Endocannabinoids as a Target for the Treatment of Traumatic Brain Injury
Technical Report,04 Oct 2010,03 Oct 2015
Louisiana State University Health Sciences Center New Orleans United States
Pagination or Media Count:
Traumatic brain injury TBI is characterized by neuroinflammation and oxidative stress as well as impaired neurocognitive function Our studies have revealed protective effects of endocannabinoid EC degradation inhibitors administered systemically 30 min post-TBI. We show marked suppression of astrocyte and microglia activation, improved neurobehavioral function, attenuation of blood brain barrier leak, and decreased glutamatergic excitability. These findings indicate that EC degradation inhibition post-TBI is neuroprotective.